Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Man3-siRNA is a synthetic small interfering RNA (siRNA) conjugated with a trimannose (Man3) ligand, designed for targeted gene silencing via the RNA interference pathway. The Man3 ligand is intended to direct the siRNA specifically to cells expressing mannose receptors (for example, antigen-presenting cells or macrophages), enhancing cellular uptake through receptor-mediated endocytosis. Once internalized, the siRNA duplex is incorporated into the RNA-induced silencing complex (RISC), which then uses the antisense strand to bind complementary messenger RNA (mRNA), facilitating its cleavage and degradation. This prevents protein translation and results in targeted gene knockdown. Man3-siRNA is a research or preclinical agent leveraging synthetic siRNA for selective, sequence-dependent inhibition of gene expression at the mRNA level[1][2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Man3-siRNA.